Carbamic Acid

Carbamic Acid

SCHEMBL6323883

Cc1cccc2[nH]c(N)nc12.NC(=O)O

nearest known ligand 0.81

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.54
TDP1 Q9NUW8 1/20 0.54
PARP1 P09874 1/20 0.49
HPSE Q9Y251 1/20 0.48
MGAM O43451 10/20 0.48
GAA P10253 10/20 0.48
SI P14410 10/20 0.48
MGAM2 Q2M2H8 10/20 0.48
HRH4 Q9H3N8 1/20 0.47
KDM4E B2RXH2 1/20 0.47
NPC1 O15118 1/20 0.47
TP53 P04637 1/20 0.47
HPGD P15428 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HSD17B10 Q99714 1/20 0.47
ATP4A P20648 1/20 0.45
ATP4B P51164 1/20 0.45
NUDT1 P36639 2/20 0.45
ESR1 P03372 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL727228 0.90 MGAM (0.53) ALDH1A1MGAMGAASIMGAM2
SCHEMBL3137529 0.79 HRH4 (0.58) ALDH1A1TDP1PARP1HPSEMGAM
Carbamic Acid SCHEMBL6315736 0.77 RPS6KA3 (0.51) PARP1NUDT1
SCHEMBL6842051 0.77 PARP1 (0.69) PARP1
SCHEMBL1144691 0.77 HRH4 (0.59) ALDH1A1TDP1HPSEMGAMGAA
SCHEMBL8260543 0.77 KDM4E (0.60) PARP1KDM4EHPGD
SCHEMBL1193115 0.75 PARP1 (0.54) PARP1KDM4EHPGDNUDT1
SCHEMBL3420273 0.75 PARP1 (0.50) ALDH1A1TDP1PARP1HPSEMGAM
Carbamic Acid SCHEMBL6323888 0.74 TYMS (0.44) ALDH1A1PARP1GAAKDM4ENUDT1
SCHEMBL3413861 0.74 HPSE (0.55) ALDH1A1TDP1HPSEMGAMGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050288348-A1 Compounds and methods for use thereof in the treatment of cancer UAF TECHNOLOGIES AND RESEARCH, LLC (US) 2005-12-29 US disclosed
US-6930121-B2 Compounds and methods for use thereof in the treatment of viral infections UAF TECHNOLOGIES AND RESEARCH, LLC (US) 2005-08-16 US disclosed
US-6916836-B2 Compounds and methods for use thereof in the treatment of viral infections UAF TECHNOLOGIES AND RESEARCH, LLC (US) 2005-07-12 US disclosed
US-6720349-B2 BENZIMIDAZOLE DERIVATIVES AND SALTS AND PRODRUGS THEREOF UAF TECHNOLOGIES AND RESEARCH, LLC 2004-04-13 US disclosed
US-20040029942-A1 Compounds and methods for use thereof in the treatment of viral infections UNIVERSITY OF ARIZONA FOUNDATION 2004-02-12 US disclosed
US-6608096-B1 2-N-alkylurea Benzimidazole derivatives UNIVERSITY OF ARIZONA FOUNDATION 2003-08-19 US disclosed
EP-1330441-A2 BENZIMIDAZOLES AND METHODS FOR USE THEREOF IN THE TREATMENT OF CANCER OR VIRAL INFECTIONS The University of Arizona Foundation (US) 2003-07-30 EP disclosed
US-20030100592-A1 Compounds and methods for use thereof in the treatment of viral infections UNIVERSITY OF ARIZONA FOUNDATION (US) 2003-05-29 US disclosed
US-20020193609-A1 Compounds and methods for use thereof in the treatment of cancer or viral infections THE PROCTER & GAMBLE COMPANY 2002-12-19 US disclosed
US-6462062-B1 N-ESTER OR AMIDE SUBSTITUTED 2-AMINO-BENZIMIDAZOLES THE PROCTER & GAMBLE COMPANY 2002-10-08 US disclosed
US-6407105-B1 2-AMINO-1-CARBOXYBENZIMIDAZOLE DERIVATIVES; VIRICIDES, ANTITUMOR AGENTS, ANTICARCINOGENIC AGENTS THE PROCTER & GAMBLE COMPANY 2002-06-18 US disclosed
US-6380232-B1 FOR THERAPY OF CANCER OR A VIRAL INFECTION IN WARM BLOODED ANIMALS, MAY BE USED IN COMBINATION WITH POTENTIATOR OR OTHER DRUG THE PROCTER & GAMBLE COMPANY 2002-04-30 US disclosed
WO-2002026716-A2 BENZIMIDAZOLES AND METHODS FOR USE THEREOF IN THE TREATMENT OF CANCER OR VIRAL INFECTIONS THE PROCTER & GAMBLE COMPANY (US) 2002-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100592-A1 Compounds and methods for use thereof in the treatment of viral infections PAICS, PIGO, BAD ALDH1A1 260/4885TDP1 1614/4885PARP1 1133/4885
US-20040029942-A1 Compounds and methods for use thereof in the treatment of viral infections PAICS, PIGO, BAD ALDH1A1 260/4885TDP1 1614/4885PARP1 1133/4885
US-20050288348-A1 Compounds and methods for use thereof in the treatment of cancer PAICS, BAD, PIGO ALDH1A1 127/4885TDP1 1431/4885PARP1 1039/4885
US-20020193609-A1 Compounds and methods for use thereof in the treatment of cancer or viral infections PAICS, MCL1, BAD ALDH1A1 204/4885TDP1 1408/4885PARP1 1094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.